Earnings
Home›Earnings›Results›ANI Pharmaceuticals reports record Q2 revenue, Cortrop…
ANI Pharmaceuticals reports record Q2 revenue, Cortrophin Gel growth
Cortrophin Gel sales rose 43% year over year, and the company revised full-year Cortrophin Gel guidance to $520 million to $540 million.
ANI Pharmaceuticals reported record quarterly revenue and adjusted EBITDA, driven by a 43% year-over-year increase in Cortrophin Gel sales, according to a Yahoo Finance summary of the company’s Q2 2026 earnings call.
The company said it completed its single largest rare disease sales force expansion in company history, increasing headcount by 50% to about 180 representatives targeting the acute gouty arthritis market.
ANI Pharmaceuticals maintained a dominant position in the generics market as the No. 2 player in Competitive Generic Therapy filings, and it said it uses cash flow to fund rare disease research and development and commercial infrastructure.
The company revised Cortrophin Gel annual guidance to $520 million to $540 million based on first-half results, while it expects sequential revenue and adjusted EBITDA growth in Q4 2026 as the gout-focused sales force reaches full operational maturity and seasonal insurance tailwinds take effect.